

Human and Mouse ORFeome Collaboration Clones


Distributed through K.K. DNAFORM

Vector Map: pENTR223

NAME: pENTR223
RESISTANT MARKER: Spectinomycin resistant; 100 µg/ml
SOURCE: Dana Farber Cancer Institute/Vidal Lab
V_TYPE: Gateway entry vector
SEQUENCING PRIMERS: M13(-21), T7

Note the specific antibiotic to be used with this vector.
Confirm sequencing primer sequences match vector before sequencing.

Map



POLYLINKER SEQUENCE:

CAACAGATAAAAACGAAAGGCCAGTCTTCCGACTGAGCCTTTTCGTTTTAT
 TTGATGCCTGGCAGTTCCCTACTCTCGCGTTAACGCTAGCATGGATGTTT
 TCCCAGTCACGACGT**TGTA AACGACGGCCAGT**CTTAAGCTCGGGCCCCA
 AATAATGATTTTTATTTGACTGATAGTGACCTGTTCTGTTGCAACAAATTG
 ATGAGCAATGCTTTTTTTATAATGCCAACTTTGTACAAAAAAGTTG-**linker-ORF-linker**-
 CCAACTTTCTTGTACAAAGTTGGCATTATAAGAAAAG
 CATTGCTTATCAATTTGTTGCAACGAACAGGTCCTATCAGTCAAAATAA
 AATCATTATTTGCCATCCAGCTGATATCCCCCTATAGTGAGTCGTATTACA
 TGGTCATAGCTGTTTCTGGCAGCTCTGGCCCGTGTCTCAAATCTCTGA
 TGTTACATTGCACAAGATAAAAAATATATCATCATGCCTCCTCTAGACCAG
 CCAGGACAGAAATGCCTCGACTTCGCTGC

Sequence:

1	CTTTCCTGCG	TTATCCCCTG	ATTCTGTGGA	TAACCGTATT	ACCGCCTTTG	AGTGAGCTGA	60
61	TACCGCTCGC	CGCAGCCGAA	CGACCGAGCG	CAGCGAGTCA	GTGAGCGAGG	AAGCGGAAGA	120
121	GCGCCCAATA	CGCAAACCGC	CTCTCCCCGC	GCGTTGGCCG	ATTCATTAAT	GCAGCTGGCA	180
181	CGACAGGTTT	CCCGACTGGA	AAGCGGGCAG	TGAGCGCAAC	GCAATTAATA	CGCGTACCGC	240
241	TAGCCAGGAA	GAGTTTGTAG	AAACGCAAAA	AGGCCATCCG	TCAGGATGGC	CTTCTGCTTA	300
301	GTTTGATGCC	TGGCAGTTTA	TGGCGGGCGT	CCTGCCCGCC	ACCCTCCGGG	CCGTTGCTTC	360
361	ACAACGTTCA	AATCCGCTCC	CGGCGGATTT	GTCTACTCA	GGAGAGCGTT	CACCGACAAA	420
421	CAACAGATAA	AACGAAAGGC	CCAGTCTTCC	GACTGAGCCT	TTCGTTTTAT	TTGATGCCTG	480
481	GCAGTTC CCT	ACTCTCGCGT	TAACGCTAGC	ATGGATGTTT	TCCCAGTCAC	GACGTTGTAA	540
541	AACGACGGCC	AGTCTTAAGC	TCGGGCCCCA	AATAATGATT	TTATTTTGAC	TGATAGTGAC	600
601	CTGTTCTGTTG	CAACAAATTTG	ATGAGCAATG	CTTTTTTATA	ATGCCAACTT	TGTACAAAAA	660
661	AGTTGCCAAC	TTTCTTGTAC	AAAGTTGGCA	TTATAAGAAA	GCATTGCTTA	TCAATTTGTT	720
721	GCAACGAACA	GGTCACTATC	AGTCAAAATA	AAATCATTAT	TTGCCATCCA	GCTGATATCC	780
781	CCTATAGTGA	GTCGTATTAC	ATGGTCATAG	CTGTTTCTTG	GCAGCTCTGG	CCCGTGTCTC	840
841	AAAATCTCTG	ATGTTACATT	GCACAAGATA	AAAAATATC	ATCATGCCCT	CTCTAGACCA	900
901	GCCAGGACAG	AAATGCCCTCG	ACTTCGCTGC	TACCCAAGGT	TGCCGGGTGA	CGCACACCGT	960
961	GGAACCGGAT	GAAGGCACGA	ACCCAGTGGA	CATAAGCCTG	TTCGTTTCGT	AAGCTGTAAT	1020
1021	GCAAGTAGCG	TATGCGCTCA	CGCAACTGGT	CCAGAACCTT	GACCGAACGC	AGCGGTGGTA	1080
1081	ACGGCGCAGT	GGCGGTTTTT	ATGGCTTGTT	ATGACTGTTT	TTTTGGGGTA	CAGTCTATGC	1140
1141	CTCGGGCATC	CAAGCAGCAA	GCGCGTTACG	CCGTGGGTCG	ATGTTTGATG	TTATGGAGCA	1200
1201	GCAACGATGT	TACGCAGCAG	GGCAGTCGCC	CTAAAACAAA	GTAAACATC	ATGAGGGAAG	1260
1261	CGGTGATCGC	CGAAGTATCG	ACTCAACTAT	CAGAGGTAGT	TGGCGTCATC	GAGCGCCATC	1320
1321	TCGAACCGAC	GTTGCTGGCC	GTACATTTGT	ACGGCTCCGC	AGTGGATGGC	GGCCTGAAGC	1380
1381	CACACAGTGA	TATTGATTTG	CTGGTTACGG	TGACCGTAAG	GCTTGATGAA	ACAACGCGGC	1440
1441	GAGCTTTGAT	CAACGACCTT	TTGGAAACTT	CGGCTTCCCC	TGGAGAGAGC	GAGATTCTCC	1500
1501	GCGCTGTAGA	AGTCACCATT	GTTGTGCACG	ACGACATCAT	TCCGTGGCGT	TATCCAGCTA	1560
1561	AGCGCGAACT	GCAATTTGGA	GAATGGCAGC	GCAATGACAT	TCTTGCAGGT	ATCTTCGAGC	1620
1621	CAGCCACGAT	CGACATTGAT	CTGGCTATCT	TGCTGACAAA	AGCAAGAGAA	CATAGCGTTG	1680
1681	CCTTGGTAGG	TCCAGCGGGC	GAGGAACTCT	TTGATCCGGT	TCCTGAACAG	GATCTATTTG	1740
1741	AGGCGCTAAA	TGAAACCTTA	ACGCTATGGA	ACTCGCCGCC	CGACTGGGCT	GGCGATGAGC	1800
1801	GAAATGTAGT	GCTTACGTTG	TCCCGCATTT	GGTACAGCGC	AGTAACCGGC	AAAATCGCGC	1860
1861	CGAAGGATGT	CGTGCCGAC	TGGGCAATGG	AGCGCTGGC	GGCCCAGTAT	CAGCCCCTCA	1920
1921	TACTTGAAGC	TAGACAGGCT	TATCTTGGAC	AAGAAGAAGA	TCGCTTGGCC	TCGCGCGCAG	1980
1981	ATCAGTTGGA	AGAATTTGTC	CACTACGTGA	AAGGCGAGAT	CACCAAGGTA	GTCGGCAAAT	2040
2041	AACCCTCGAG	CCACCCATGA	CCAAAATCCC	TTAACGTGAG	TTACGCGTCG	TTCCACTGAG	2100
2101	CGTCAGACCC	CGTAGAAAAG	ATCAAAGGAT	CTTCTTGAGA	TCCTTTTTTT	CTGCGCGTAA	2160
2161	TCTGCTGCTT	GCAAACAAAA	AAACCACCGC	TACCAGCGGT	GGTTTGTTTG	CCGGATCAAG	2220
2221	AGCTACCAAC	TCTTTTTCCG	AAGGTAAC TG	GCTTCAGCAG	AGCGCAGATA	CCAAATACTG	2280
2281	TCCTTCTAGT	GTAGCCGTAG	TTAGGCCACC	ACTTCAAGAA	CTCTGTAGCA	CCGCCTACAT	2340
2341	ACCTCGCTCT	GCTAATCCTG	TTACCAGTGG	CTGCTGCCAG	TGGCGATAAG	TCGTGTCTTA	2400
2401	CCGGGTTGGA	CTCAAGACGA	TAGTTACCGG	ATAAGGCGCA	GCGGTGGGGC	TGAACGGGGG	2460
2461	GTTCTGTCAC	ACAGCCCAGC	TTGGAGCGAA	CGACCTACAC	CGAACTGAGA	TACCTACAGC	2520
2521	GTGAGCATTG	AGAAAGCGCC	ACGCTTCCCG	AAGGGAGAAA	GGCGGACAGG	TATCCGGTAA	2580
2581	GCGGCAGGGT	CGGAACAGGA	GAGCGCACGA	GGGAGCTTCC	AGGGGGAAAC	GCCTGGTATC	2640
2641	TTTATAGTCC	TGTCGGGTTT	CGCCACCTCT	GACTTGAGCG	TCGATTTTTG	TGATGCTCGT	2700
2701	CAGGGGGGCG	GAGCCTATGG	AAAAACGCCA	GCAACGCGGC	CTTTTTACGG	TTCTGGCCT	2760
2761	TTTGCTGGCC	TTTTGCTCAC	ATGTT			2785	

All ORF clones are provided in Entry Vectors for the Invitrogen Gateway® cloning system. Invitrogen offers a whole range of Destination Vectors for a wide range of applications. Refer to the homepage of Invitrogen for further information on the Gateway® cloning system and related Invitrogen products at:

<http://www.invitrogen.com/content.cfm?pageid=4072>

For further information on the ORFeome Collaboration, visit their homepage at <http://www.orfeomecollaboration.org/html/index.shtml>.

For further technical information visit our homepage at: <http://www.dnaform.jp> or contact us under: techinfo@dnaform.jp.

Contact Address

K.K. DNAFORM – *Precision Gene Technologies*
Leading Venture Plaza-2
75-1, Ono-cho, Tsurumi-ku, Yokohama City
Kanagawa 230-0046
Japan

Tel: +81-(0)45-510-0607
Fax: +81-(0)45-510-0608
e-mail: techinfo@dnaform.jp
Homepage: <http://www.dnaform.jp>